Recent Company News

• 09:58 PM ET Feb 09, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 05:12 PM ET Feb 09, 2026
  

  Sino Biopharmaceutical completes subject enrollment in phase iii clinical trial of TQB2102 for HER2-LOW breast cancer (HK$6.60, 0.00)

• 05:20 PM ET Feb 08, 2026
  

  Sino Biopharmaceutical completes subject enrollment for Phase III trial of LM-302 in gastric and gastroesophageal junction adenocarcinoma (HK$6.48, 0.00)

• 01:03 AM ET Feb 04, 2026
  

  StreetAccount Sector Summary - China Healthcare January Recap

• 03:36 AM ET Jan 27, 2026
  

  Sino Biopharmaceutical reports TQA3605 phase II clinical trial has reached primary endpoint (HK$6.67, 0.00)

• 09:23 AM ET Jan 20, 2026
  

  StreetAccount M&A Summary: Week of 12-Jan

• 01:36 PM ET Jan 15, 2026
  

  Transcript Intelligence: Sino Biopharmaceutical at J.P. Morgan Healthcare Conference (HK$7.00, 0.00)

• 05:55 PM ET Jan 14, 2026
  

  Street Takeaways - Sino Biopharmaceutical's acquisition of Hygieia (HK$7.11, 0.00)

• 04:46 AM ET Jan 13, 2026
  

  Sino Biopharmaceutical acquires Hygieia for maximum base consideration of CNY1.20B (HK$6.91, 0.00)

• 11:51 PM ET Dec 30, 2025
  

  Sino Biopharmaceutical enrolls first patient in Phase III clinical trial of TDI01 "ROCK2 inhibitor" for treatment of idiopathic pulmonary fibrosis (HK$6.18, -0.10)